Research Article

Sirt-1 Regulates Physiological Process and Exerts Protective Effects against Oxidative Stress

Lei Liu,1,2,3 Guangyuan Xia,2,4 Peifan Li,2 Yiming Wang,2,4 and Qian Zhao5

1Department of Mental Health and Psychiatry, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China 215006
2Department of Psychiatry, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China 550025
3Department of Psychiatry, Zaozhuang Mental Health Center, Zaozhuang, Shandong, China 277103
4College Students’ Mental Health Education and Counseling Center, Guizhou Medical University, Guiyang, Guizhou, China 550004
5Department of Nuclear Medicine, General Hospital of Ningxia Medical University, Ningxia, Ningxia Hui Autonomous Region, China 750004

Correspondence should be addressed to Yiming Wang; 754603457@qq.com and Qian Zhao; cecilia_hh@126.com

Received 20 February 2021; Revised 5 March 2021; Accepted 10 March 2021; Published 24 March 2021

Academic Editor: Yuzhen Xu

Copyright © 2021 Lei Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Recent studies suggest a correlation between the reduced Sirt-1 expression with Alzheimer’s diseases (AD) and depression, respectively, suggesting a possible pathogenic role of the altered Sirt-1 expression in neuronal degenerative diseases, such as AD and depression. However, the molecular mechanisms underlying how Sirt-1 reduction impairs neuronal functions remain unknown. Methods. We used the SK-N-SH neuroblastoma cells to study the role of Sirt-1 expression on physiological roles in neuronal cells. Gain of Sirt-1 was achieved by transiently transfecting Sirt-1 expression plasmid. Sirt-1-specific shRNA was used to elucidate the role of Sirt-1 loss of function. CCK-8 (Cell Counting Kit-8) assay and flow cytometry were used to evaluate cell proliferation. Semiquantitative western blotting was used to detect relative protein levels. A further luciferase reporter gene assay was employed to examine the effect of Sirt-1 expression on the transcriptional activity of p53. RT-qPCR was used to determine the mRNA levels of p21, Bax, and Bcl-2, which were the downstream target genes of p53. Results. Sirt-1 suppressed the p53 downstream gene p21 transcription, while shRNA-mediated Sirt-1 knockdown resulted in a significant increase in p21 expression, implying a possibility that Sirt-1 promotes neuron proliferation through suppressing p53 transcriptional activity. The mRNA and protein levels of p53 were not affected by the altered Sirt-1 expression, suggesting that Sirt-1 regulates the transcriptional regulatory activity of p53 rather than p53 expression. Indeed, we further confirmed that Sirt-1 appeared to inhibit p53 transcriptional activity by attenuating its acetylation and resulted in a decrease of p53’s binding to the p21 promoter. Overexpressed Sirt-1 scavenged reactive oxygen species (ROS) production in SK-N-SH with \( \text{H}_2\text{O}_2 \). Knockdown of Sirt-1 presented opposite effect; the addition of EX527 (Sirt-1 inhibitor) increased ROS accumulation. Conclusions. Oxidative stress induces Sirt-1 in neuron cells, and Sirt-1 promotes proliferation in SK-N-SH cells, which protects them from oxidative stress-induced cell death, potentially via suppressing the transcriptional activity of p53. These results provide a molecular explanation underlying how the reduced Sirt-1 potentially causes the AD and depression-related diseases, supporting the idea that Sirt-1 can possibly be used as a diagnostic biomarker and/or therapeutic drug target for the AD and depression-related diseases.

1. Introduction

Silent mating type information regulation 2 homolog 1 (Sirt-1), which is a member of the sirtuin family, exerts stress-protecting effects against inhibition of cell cycle entry and induction of apoptotic cell death via transcriptionally regulating gene expression [1]. Sirt-1 is one of the nicotinamide adenine dinucleotide- (NAD⁺-) dependent histone deacetylases and is discovered to be a critical component of seven homologous proteins regulating cell functions through chromatin remodeling/histone deacetylation [2–4]. In these manners, Sirt-1 plays critical roles in many human physiological
functions, including DNA repair, aging, gene expression, and apoptosis [5]. In mouse C2C12 myoblasts, Sirt-1 was found to inhibit the differentiating processes and expression of myogenin, which resulted in the proliferating inhibition and maturation of cell lines [6, 7]. Oberdoerffer and colleagues reported that, in mammalian cells, including in neurons, Sirt-1 was triggered by DNA damage and then redistributed to DNA breaks for repairmen, functioning as a transcriptional regulator [8]. Notably, Sirt-1 was also found to be a neuroprotective molecule, which protected neurons against oxidative stress-induced cellular damage and stressful perturbations in both acute and chronic neurological diseases, including AD [9, 10]. In animal models of AD and Huntington’s disease, overexpression of Sirt-1 abrogated neuronal degeneration and nonapoptotic and apoptotic cell death and indicated the tight association of Sirt-1 to physiological processes in neurons.

Sirt-1 interacts with several target substrates, including forkhead box O (FOXO) family members and p53 [11–13]. It was shown that in mammalian cells, Sirt-1 appeared to control the cellular response to stress by interacting with the FOXO family of forkhead transcription factors and thus exerting protective effects against oxidative stress-induced cellular damage [14]. By exerting deacetylating activity, Sirt-1 inactivates p53 and thus regulates cell survival and proliferation [13]. Suppression of Sirt-1 resulted in hyperacetylation of p53, which prevented its binding to Mdm2, resulting in cell cycle arrest and apoptosis [13]. The cyclin-dependent kinase (CDK) inhibitor p21 is a critical regulator in the cell cycle checkpoint resulting in the inhibition of G1 progression and induction of senescence by blocking the activity of CDKs, without knowing how cell cycle is blocked [15, 16]. p21, which is one of the most well-known p53 target genes, is tightly transcriptionally regulated by deacetylated p53 and results in p53-dependent G1 arrest after DNA damage [17]. By considering the regulation of Sirt-1 on FOXO and p53, we hypothesized that Sirt-1 might exert protective effects in neurons by deacetylating FOXO and p53.

Oxidative stress is a state which might either generates or accumulates the levels of cellular reactive oxygen species (ROS) [18]. Increasing ROS may dysfunctions mitochondrial, damaging lipids, proteins, and DNA, which are consistently observed in AD subject autopsy brains [19]. In recent years, oxidative stress is recognized as a central factor in major depressive disorder (MDD) and AD. Oxidative stress-induced ROS accumulation causes brain damage and triggers specific antioxidant defense, including increasing the expression level of amyloid-β and accumulation of hyperphosphorylated tau, leading to complex pathological cascades culminating in AD [20–22]. In the rat brain, activation of Sirt-1 inhibited p53 acetylation and ROS production, which was further promoted by the addition of EX527, a Sirt-1 inhibition, which indicated that Sirt-1 might exert a protective effect against oxidative stress-related AD, by deacetylating p53 and thus scavenged ROS accumulation [23].

Here, we aimed to investigate whether Sirt-1 might protect neuronal cells against oxidative stress by regulating FOXO or p53. SK-N-SH neuroblastoma cells were employed to figure out the roles of Sirt-1 expression on physiological roles in neuronal cells. This study determined for the first time that Sirt-1 might regulate p53 depending on its deacetylation activity and scavenge ROS induced by oxidative stress, demonstrating the importance of Sirt-1 and oxidative-induced ROS in the progression of AD and relative diseases.

2. Material and Methods

2.1. Cell Culture and Treatment. SK-N-SH cells (human neuroblastoma cell line) and SK-N-AS (p53-null cell line) were purchased from the Chinese Academy of Sciences (Beijing, China). As described by Huang et al. [24], SK-N-SH cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco, USA) at 37°C in a 5% CO2 humidified atmosphere, with 10% fetal bovine serum (FBS, Gibco, USA) and 1% penicillin. When cells were 70–80% confluent, Opti-MEM was used with 2 h prior to transfection.

2.2. siRNA Transfection. We followed the methods of Kobayashi et al. [25]. The Sirt-1-specific si-Sirt-1 (GenePharma, China) was synthesized to knockdown the expression of Sirt-1 in cells. The sequence of si-Sirt-1 and siRNA-NC were provided by GenePharma (China). siRNA transfection was conducted according to the manufacturer’s instructions. After transfection for 72 h, total protein and RNAs were prepared for western blotting analysis and qPCR, respectively.

2.3. Western Blotting. Cells were lysed, and BCA assay (Beyotime Biotechnology, China) was used for detecting the protein concentration. Western blotting was conducted by the methods of Xu et al. [26]. Primary antibodies were as follows: Sirt-1, Abcam, #ab220807; FOXO1, Abcam, #ab78316; p53 (acetyl K382), Abcam, #ab75754; p53 (acetyl K120), Abcam, #ab26; p21, Abcam, #ab109520; p53 (acetyl K382), Abcam, #ab75754; p53 (acetyl K120), Abcam, #ab78316. β-Actin was used as an internal control. The chemiluminescence detection kit ECL (Millipore, USA) was used to detect the bound antibodies.

2.4. Luciferase Reporter Assay. To evaluate the interaction between Sirt-1 and the Nanog 3′-UTR, the dual-luciferase reporter assay (Promega, USA) was conducted. The Nanog 3′-UTR and the mutant Nanog 3′-UTR were cloned and sequenced. We followed the methods of Xu et al. [26]. After transfection for 48 h, luciferase activity was detected and normalized with the Dual-Luciferase Reporter Assay System (Beyotime Biotechnology, Haimen, China).

2.5. CCK-8 Assay. We followed the methods of Wang et al. [27]. CCK-8 assay was conducted by using Cell Counting Kit-8 (AbMole Bioscience, USA). Cells were seeded into a 96-well plate (5.0 × 103/well) and exposed to si-RNA or not for 1 to 5 days. Then, 10 μL CCK-8 was added and cells were further incubated for 4 h. A microplate absorbance reader (Bio-Rad) was used to detect cell viability at 490 nm.

2.6. Apoptosis Analysis. Apoptosis analysis was conducted with the annexin V-FITC apoptosis assay kit (Abcam, Britain) according to kit instruction, as described by Qi et al. [28]. Cells (5 × 105–1 × 106/mL) were suspended in 200 μL
binding buffer; 10 μL annexin V-FITC were added, and cells were incubated in the dark, 4°C for 30 minutes. Then, 300 μL binding buffer and 5 μL PI were added and cell apoptosis was tested on the machine within 1 hour.

2.7. Colony Formation in Soft Agar. As described by Xu et al. [26], 1 × 10^5 cells were mixed with 0.3% low melting agar, supplemented with DMEM (including 10% FBS). Then, cells were plated on a low melting agar-coated 6-well plate (0.6%) and incubated at 37°C for 15 days. Cells were stained with crystal violet (0.05%, 0.2 mL/well) for 30 min, at 37°C. The numbers of positive colonies (>8 cells/colony) were counted. The test was repeated twice.

2.8. EdU (5-Ethynyl-2′-Deoxyuridine) Staining. We followed the methods of Zeng et al. [29]. Cells (2 × 10^5/well) in a 6-well plate were supplemented with DMEM containing 50 Mm EdU (RiboBio, Guangzhou, China) for 2 hours. The cells were washed (4°C) and fixed with 4% paraformaldehyde (at room temperature) for 10 min. EdU immunostaining was conducted with Apollo staining reaction buffer. Stained cells were observed under the fluorescence microscope (Olympus, Melville, NY).

2.9. Cell Cycle Analysis. As described by Qi et al. [28], cell cycle analysis was conducted with the Cell Cycle Analysis Kit (BioVision, USA) according to kit instruction. Cells were suspended and washed with PBS three times. Then, a cell pellet was fixed with 70% alcohol (ice-cold) at 4°C overnight. Then, cells were washed with PBS (ice-cold). 400 μL PI solution (5 μg/mL) was added to the cells for 0.5 h in the dark. Then, cell cycle was analyzed by flow cytometers (Beckman Coulter, Brea, CA, USA).

2.10. Chromatin Immunoprecipitation. As described by Zhang et al. [30, 31], chromatin from cell cultures at 0 and 24 h was prepared. Chromatin was immunoprecipitated with 4 μg of Sp1 antibody (Abcam, Britain). In parallel immunoprecipitation procedures, 4 μg of C_{aq} antibody (Santa Cruz Biotechnology, USA) was used as a control. Precipitated DNA was amplified for 25 cycles. The promoter-specific forward primer is CTGTTTTTCAGTGCCCAACT, and the reverse primer is CATGGGGGCCCCTCGCCGCTG.

2.11. Invasion Assay. Cells were suspended with a serum-free medium with the concentration of 2 × 10^5/mL. We followed the methods of Wang et al. [32]. Nine random fields were counted under the microscope, and the statistical results were obtained.

2.12. ROS Analysis. Cells were suspended with a serum-free medium with the concentration of 2 × 10^5/mL. We followed the methods of Schieber and Chandel [19]. Nine random fields were counted under laser scanning confocal microscopy, and the statistical results were obtained.

2.13. Statistical Analysis. Statistical analysis was conducted by SPSS 20.0 software (IBM). The data was presented as x ± s. t-test was used for comparison between two groups. ANOVA was used for comparison among multiple groups. P < 0.05 were considered statistically significant.

3. Results

3.1. Sirt-1 Promotes Cell Proliferation of SK-N-SH Neuronal Precursor Cells. In order to study the possible functions of Sirt-1 protein in nerve cells/neural precursor cells, SK-N-SH cells were used. We tested the impact of altered Sirt-1 expression either by transient overexpression or by small RNA interference. Western blotting analysis validated that siRNA largely diminished Sirt-1 expression in SK-N-SH cells in a dose-dependent manner; in contrast, transient transfection resulted in a 2- to 3-fold increase in Sirt-1 protein expression (Figures 1(a) and 1(b)). Importantly, suppression of Sirt-1 expression resulted in a significant reduction in SK-N-SH cell proliferation as analyzed by the CCK-8 method (Figure 1(c)). Conversely, overexpressing Sirt-1 dramatically enhanced the cell growth. When cell viability was significantly enhanced, proliferation-positive cells were increased, and Sirt-1 appears to promote SK-N-SH cell growth through facilitating their cell cycle progression because cells at G_{1}/G_0 were significantly reduced and those at the S or M phase were increased (Figure 1(e)), indicating that Sirt-1 affected the level of cell proliferation by regulating cell cycle. These results demonstrate that Sirt-1 is a positive regulator for neuronal cell proliferation and promotes cell growth through either enhancing cell cycle progression or inhibiting cell apoptosis or both.

3.2. Sirt-1 Selectively Inhibits the p53-p21 Pathway in SK-N-SH Cells. It has been shown that Sirt-1 regulates cell growth and survival through targeting p53 and FOXO1 [17]. We then speculated which pathway is regulated by Sirt-1 to promote SK-N-SH cell growth. The protein expression levels of p53 and FOXO1 were unaltered neither by Sirt-1 knockdown nor by its overexpression (Figure 2(a)). We then reasoned whether Sirt-1 regulates the transcription of p53 and FOXO1. Indeed, Sirt-1 expression inhibited, which its knockdown enhanced the luciferase activity driven by p53 (Figure 2(b)). As a control, the p53-specific inhibitor largely abolished p53 reporter activity (Figure 2(b)). Those results clearly indicate that Sirt-1 is a negative regulator of p53 transcriptional activity.

3.3. Sirt-1 Suppresses p53 Binding to p21 Promoter. To determine whether Sirt-1 attenuates p21 mRNA transcription in a p53-dependent manner, we tested the effects of p53 inhibitor pitthrin-α pretreatment on Sirt-1-mediated p21 suppression. As expected, pitthrin-α pretreatment totally abolished the increase in p21 expression by Sirt-1 knockdown (Figures 3(a) and 3(b)). Together with the fact that neither p53 mRNA nor its protein expression levels were altered by Sirt-1, these results suggest that Sirt-1 inhibits p21 transcription possibly through a p53-dependent manner.

We then used chromatin immunoprecipitation to detect changes in the binding activity of p53 to the p21 promoter region after Sirt-1 overexpression/interference. 3′-UTR of DHFR was used as a target negative control. As was shown
in Figure 3(c), the binding activity of p53 to p21 was decreased when interfered with Sirt-1 and increased when overexpression of Sirt-1.

3.4. Sirt-1 Exerts Its Deacetylation Activity on p53’s Lysine 382 and Thus Regulates Cell Proliferation. First, we examined whether the acetylation of p53 was regulated by Sirt-1, which had been known critical for p53 transcriptional activation [33]. The results showed that (Figure 4(a)), the expression of Sirt-1 had no effect on the total protein level of p53, but p53 deacetylation at 382 lysine was significantly inhibited (Figure 4(b)).
To determine how Sirt-1 regulates the binding of p53 to the promoter region of downstream target genes, we performed western blot to detect the acetylation level of p53 on 382 aa. P53 was highly acetylated at the lysine residue 382, which was largely inhibited by transient transfection of Sirt-1. Conversely, shRNA-mediated Sirt-1 knockdown resulted in a significant increase in p53 acetylation (Figure 4(a)). Since acetylation of p53 is required for its promoter binding activity, we then tested whether Sirt-1-mediated p53 deacetylation inhibited its promoter binding. Indeed, ChIP analysis detected a reduction in p53 promoter binding, which was reversed by Sirt-1-specific inhibitor EX7 (Figure 4(b)). In addition, Sirt-1 knockdown enhanced p53 promoter binding activity, further addition of Sirt-1 inhibitor, while slightly increased, but not statistically significantly enhanced p53 recruitment to the promoter (Figure 4(b)). Further analysis revealed similar changes of Sirt-1 catalytic activity in the cell lysate parallelly prepared as in Figure 4(b), suggesting regulation of p53 transcriptional activity relies on its deacylative activity.

To determine how Sirt-1 regulates the binding of p53 to the promoter region of downstream target genes, we performed western blot to detect the acetylation level of p53 on 382 aa. P53 was highly acetylated at the lysine residue 382, which was largely inhibited by transient transfection of Sirt-1. Conversely, shRNA-mediated Sirt-1 knockdown resulted in a significant increase in p53 acetylation (Figure 4(a)). Since acetylation of p53 is required for its promoter binding activity, we then tested whether Sirt-1-mediated p53 deacetylation inhibited its promoter binding. Indeed, ChIP analysis detected a reduction in p53 promoter binding, which was reversed by Sirt-1-specific inhibitor EX7 (Figure 4(b)). In addition, Sirt-1 knockdown enhanced p53 promoter binding activity, further addition of Sirt-1 inhibitor, while slightly increased, but not statistically significantly enhanced p53 recruitment to the promoter (Figure 4(b)). Further analysis revealed similar changes of Sirt-1 catalytic activity in the cell lysate parallelly prepared as in Figure 4(b), suggesting regulation of p53 transcriptional activity relies on its deacylative activity.
More importantly, Sirt-1 enhanced, but its knockdown resulted in an inhibition of the cell cycle progression (Figure 4(d)). Collectively, these results suggest that Sirt-1 regulates cell cycle progression through deacetylating p53 to attenuate its transcriptional activity.

3.5. Sirt-1 Failed to Affect Cell Proliferation in SK-N-AS Cells. To further confirm whether Sirt-1 affects cell proliferation via regulating p53, SK-N-AS, a p53-null cell line was employed. Sirt-1 was overexpressed or knocked down in SK-N-AS. By performing western blot, the efficient overexpression of Sirt-1 and knockdown of endogenous Sirt-1 were confirmed (Figure 5(a)). Opposite to the effects of overexpressed or knockdown Sirt-1 in SK-N-SH, modification of Sirt-1 failed to obviously affect cell proliferation (Figures 5(b) and 5(c)) and cell cycle distribution (Figure 5(d)). Taken together, Sirt-1 affects cell proliferation and distribution of cell cycle mainly via the presence of p53.

3.6. Sirt-1 Affects Cell Migration and Invasion. Knockdown or overexpression of Sirt-1, migration, and invasion were measured. Migration results validated that siRNA largely diminished Sirt-1 expression, which dramatically weakened the migration (Figure 6(a)) and invasion (Figure 6(b)) of SK-N-SH cells. In contrast, transient transfection resulted in the increase in Sirt-1 protein expression, which dramatically enhanced the migration (Figure 6(a)) and invasion (Figure 6(b)) of SK-N-SH cells.
3.7. Sirt-1 Inhibits H$_2$O$_2$-Induced Neuronal Cell Death. In addition to p53, it has been shown that Sirt-1 functions as a negative regulator for ROS production, implying a possibility that Sirt-1 may protect neurons from oxidative stress-induced cell death. After 24 h treatment with 50-250 mM H$_2$O$_2$, reactive oxygen species (ROS) was obviously increased and scavenged by adding 10 mM of NAC (Figures 7(a) and 7(b)), and thus, 200 mM of H$_2$O$_2$ was added to induce oxidative stress. Overexpressed Sirt-1 scavenged ROS production in SK-N-SH with H$_2$O$_2$, and knockdown of Sirt-1 presented opposite effect (Figures 8(a) and 8(b)). Similarly, the addition of 10 mM EX527 increased ROS accumulation, which indicated that the deacetylation activity of Sirt-1 is critical for its ROS suppressive activity (Figure 8(c)). Notably, H$_2$O$_2$ treatment obviously increased the Sirt-1 protein level without affecting p53 protein (Figure 8(d)) and decreased p53’s transcriptional activity (Figure 8(e)). Our results demonstrated that oxidative stress induced Sirt-1 in neuron cells, possibly to protect them from oxidative stress-induced cell death, through suppressing p53 transcriptional activity (Figure 8(f)).

To evaluate the protective effect of Sirt-1 from oxidative stress-induced SK-N-SH cell death, we first detect cell viability after 48-hour incubation in 200 mM H$_2$O$_2$. As it is shown in Figure 9(a), overexpressed Sirt-1 significantly improved cell viability under oxidative stress. Notably, knockdown of Sirt-1 failed to affect cell viability, possibly due to the endogenous Sirt-1 expression that remains at a low level and barely affected cell injury induced by oxidative stress. Consistent with this, inhibition of deacetylation activity of endogenous Sirt-1 by EX527 did not show any effects (Figure 9(b)). Taken together, our results show that overexpressed Sirt-1 inhibits oxidative stress-induced apoptotic cell death depending on its deacetylation activity (Figure 9(c)).

4. Discussion

Sirt-1 has been widely studied as a regulator of many cellular physiological and pathological processes [34, 35] It was also observed that Sirt-1 was associated with cognitive impairment in AD, and similar results were obtained in depression studies [36, 37]. However, how Sirt-1 affected AD or
depression is still unknown, especially the association among Sirt-1, AD, and depression. In this study, we investigated the regulation of Sirt-1 on the proliferation in SK-N-SH cells and found that Sirt-1 affects physiological processes. Modified Sirt-1 by overexpression and knockdown transcriptionally regulated p53’s downstream target gene, p21, in a p53-

Figure 6: Sirt-1 affects cell migration and invasion. Knockdown or overexpression of Sirt-1, migration (a), and invasion (b) were measured.

Figure 7: ROS level was induced after H2O2 treatment. (a) ROS staining was imaged after 24 h exposure to different concentrations of H2O2. (b) ROS level was quantitatively measured.
dependent manner. Sirt-1 regulates the transcriptional activity of p53 by inhibition of the acetylation of p53. By employing human neuroblastoma cell line SK-N-AS, which is a p53-null cell line, upregulation or downregulation of Sirt-1 failed to affect p21 and cell cycle distribution, which further confirmed the necessity of p53 on Sirt-1’s regulatory roles in Figure 2(b). The deacetylation activity of Sirt-1 is necessary to regulate physiological processes, including cell proliferation via regulating the transcriptional activity of p53, and thus regulates its downstream target genes. The above results...
suggest that Sirt-1 may be closely related to the raising of AD by exerting protective effects on neuronal cells.

We also found that Sirt-1 promotes cell proliferation via regulating cell cycle progression. Overexpression of Sirt-1 enhanced cell viability and cell proliferation by promoting the entry of cell cycle from the G1 phase to the G0 phase, which is consistent with previous studies [38, 39]. As an important member of the sirtuin family, Sirt-1 is involved in regulating cell proliferation in many human cells. In AD model animals, overexpression of Sirt-1 slowed cell death, neurodegeneration, and cognitive decline [40, 41]. Acetylshikonin, which upregulates Sirt-1, can reduce cognitive dysfunction [42]. In contrast, inhibition of Sirt-1 expression can prevent oligodendrocyte progenitor cell proliferation [43]. Downregulation of Sirt-1 in senescent microglia plays a key role in aggravating senescence in mice, while overexpression of Sirt-1 significantly prolongs life [44].

We observed that in SK-N-NH, but not in SK-N-AS, inhibition of Sirt-1 promoted the transcriptional activity of p53, but not that of FOXO1, which indicated that Sirt-1 specifically regulates p53 in SK-H-SH with wild-type p53. p53 is one of the most critical transcriptional factors to regulate nonhistone proteins [45, 46]. Acetylation of p53 increases the stability of the p53 protein and its antiviral to DNA damage, which is necessary for the detection of DNA damage and the activation of oncogenes [47, 48]. Previous literature studies have shown that Sirt-1 regulates the transcriptional regulatory activity of p53 by deacetylation of p53, which is similar to our results [20].

**Figure 9:** Sirt-1 protects cells from oxidative stress induced by H$_2$O$_2$ via its deacetylation activity. (a) Adding 200 mM H$_2$O$_2$, the percentage of cell viabilities in the vector group, Sirt-1 group, scrambled group, and shSirt-1 group were measured. Sirt-1 presence protects cells from H$_2$O$_2$-induced decrease in cell viability. *P < 0.05, vs. vector group. (b, c) The percentage of apoptosis in the vector group, Sirt-1 group, scrambled group, shSirt-1 group, and EX527 group was measured. Sirt-1 exerts protective effects on cell viability and cell survival from apoptotic cell death depending on its deacetylation activity.
Under oxidative stress, p53 promotes cell death after the failure of DNA repair [17]. Sirt-1 was reported to exert protective effects on rat neuronal cells in vivo by inhibiting p53 transcriptional activity. EX527, a Sirt-1 inhibitor, exerted similar effects to that of Sirt-1 knockdown. EX527 treatment potentially due to the induction of ROS by oxidative stress could be scavenged by activation of Sirt-1 and inhibition of p53 [19]. By considering that oxidative stress is recognized as a central stress factor in major depressive disorder (MDD) and AD, activation of Sirt-1 may prevent from MDD and AD via protecting neuronal cells from oxidative stress.

In summary, we demonstrated the important role of Sirt-1 in maintaining the proliferation and suppressing the oxidative stress-induced neuronal cell death. At the molecular level, Sirt-1 inhibits p53 transcription activation through directly deacetylating p53 and thus reduces p21 gene expression. On the other hand, Sirt-1 protects neuronal cells from oxidative stress-induced apoptosis via suppressing ROS production. These results provide a molecular explanation of the protective effect of Sirt-1 on AD and depression-related diseases and provide a rationale for Sirt-1 as a biomarker and therapeutic target for the diagnosis, treatment, and prevention of AD and depression-related diseases.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Lei Liu, Guangyuan Xia, and Peifan Li are joint first authors.

Acknowledgments

The authors thank Dr. Li Jia for her generous assistance to the manuscript. This study had support from the National Natural Science Foundation of China (Nos. 81761128036, 81960262, and 31760294), as well as supports from the High-Level Innovative Talents Cultivation Program of Guizhou Province (Qian Ke He SY[2018]5802 and [2016]5679), Guizhou Science and Technology Cooperation Support [2020] No. 4Y198, and Guiyang City Science and Technology Projects, Zhu Subjects Contract ([2018]1-94).

References

[1] W. Duan, “Sirtuins: from metabolic regulation to brain aging,” Frontiers in Aging Neuroscience, vol. 5, 2013.
[2] T. Finkel, C. X. Deng, and R. Mostoslavsky, “Recent progress in the biology and physiology of sirtuins,” Nature, vol. 460, no. 7255, pp. 587–591, 2009.
[3] M. C. Haigis and D. A. Sinclair, “Mammalian sirtuins: biological insights and disease relevance,” Annual Review of Pathology, vol. 5, no. 1, pp. 253–295, 2010.
[4] L. Guarente and H. Franklin, “Epstein lecture: sirtuins, aging, and medicine,” Journal of Medicine, vol. 364, no. 23, pp. 2235–2244, 2011.
[5] O. Grubisha, B. C. Smith, and J. M. Denu, “Small molecule regulation of Sir2 protein deacetylases,” The FEBS Journal, vol. 272, no. 18, pp. 4607–4616, 2005.
[6] M. Vinciguerra, M. Fulco, A. Ladurner, V. Sartorelli, and N. Rosenenthal, “Sirt1 in muscle physiology and disease: lessons from mouse models,” Disease Models & Mechanisms, vol. 3, no. 5-6, pp. 298–303, 2010.
[7] M. Fulco, R. L. Schiltz, S. Iezzi et al., “Sir2 regulates skeletal muscle differentiation as a potential sensor of the redox state,” Molecular Cell, vol. 12, no. 1, pp. 51–62, 2003.
[8] P. Oberdoerffer, S. Michan, M. McVay et al., “SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging,” Cell, vol. 135, no. 5, pp. 907–918, 2008.
[9] S. W. Min, S. H. Cho, Y. Zhou et al., “Acetylation of tau inhibits its degradation and contributes to tauopathy,” Neuron, vol. 67, no. 6, pp. 953–966, 2010.
[10] G. Donmez, “The neurobiology of sirtuins and their role in neurodegeneration,” Trends in Pharmacological Sciences, vol. 33, no. 9, pp. 494–501, 2012.
[11] J. J. P. Tao, Q. Wang, L. Li, and Y. Xu, “SIRT1: mechanism and protective in diabetic nephropathy,” Endocrine, Metabolic & Immune Disorders - Drug Targets, vol. 20, 2020.
[12] D. Frescas, L. Valenti, and D. Accili, “Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes,” The Journal of Biological Chemistry, vol. 280, no. 21, pp. 20589–20595, 2005.
[13] J. Yi and J. Luo, “SIRT1 and p53, effect on cancer, senescence and beyond,” Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, vol. 1804, no. 8, pp. 1684–1689, 2010.
[14] A. Brunet, L. B. Sweeney, I. F. Sturgill et al., “Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase,” Science, vol. 303, no. 5666, pp. 2011–2015, 2004.
[15] J. G. Jackson and O. M. Pereira-Smith, “p53 is preferentially recruited to the promoters of growth arrest genes p21 and GADD45 during replicative senescence of normal human fibroblasts,” Cancer Research, vol. 66, no. 17, pp. 8356–8360, 2006.
[16] W. Wei, R. M. Hemmer, and J. M. Sedivy, “Role of p14 (ARF) in replicative and induced senescence of human fibroblasts,” Molecular and Cellular Biology, vol. 21, no. 20, pp. 6748–6757, 2001.
[17] H. Xu, Y. Zhou, K. A. Coughlan et al., “AMPKα1 deficiency promotes cellular proliferation and DNA damage via p21 reduction in mouse embryonic fibroblasts,” Biochim Biophys Acta, vol. 1853, no. 1, pp. 65–73, 2015.
[18] M. P. Mattson, “Pathways towards and away from Alzheimer’s disease,” Nature, vol. 430, no. 7000, pp. 631–639, 2004.
[19] M. Schieber and N. S. Chandel, “Corrigendum to Ameliorative effect of saffron aqueous extract on hyperglycemia, hyperlipidemia, and oxidative stress on diabetic encephalopathy in streptozotocin induced experimental diabetes mellitus,” BioMed Research International, vol. 2020, 2020.
[20] C. Matrone, M. T. Ciotti, D. Mercanti, R. Marolda, and P. Calissano, “NGF and BDNF signaling control amyloidogenic route and Abeta production in hippocampal neurons,”
12 BioMed Research International

Proc Natl Acad Sci USA, vol. 105, no. 35, pp. 13139–13144, 2008.

[21] S. Kaptoge, E. D. Angelantonio, C. Moore et al., “Longer-term efficiency and safety of increasing the frequency of whole blood donation (INTERVAL): extension study of a randomised trial of 20,757 blood donors,” Lancet Haematol, vol. 6, no. 10, pp. e510–e520, 2019.

[22] X. Huang, C. S. Atwood, M. A. Hartshorn et al., “The A beta peptide of Alzheimer’s disease directly produces hydrogen peroxide through metal ion reduction,” Biochemistry, vol. 38, no. 24, pp. 7609–7616, 1999.

[23] M. Khan, S. A. Shah, and M. O. Kim, “17β-Estradiol via SIRT1/acytely-p53/NF-kb signaling pathway rescued postnatal rat brain against Acute ethanol intoxication,” Molecular Neurobiology, vol. 56, no. 4, pp. 3067–3078, 2018.

[24] T. C. Huang, H. Y. Chang, C. Y. Chen et al., “Silencing of miR-124 induces neuroblastoma SK-N-SH differentiation, cell cycle arrest and apoptosis through promoting AHR,” FEBS Letters, vol. 585, no. 22, pp. 3582–3586, 2011.

[25] Y. Kobayashi, Y. Furukawa-Hibi, C. Chen et al., “Sirt1 is critical regulator of FOXO-mediated transcription in response to oxidative stress,” International Journal of Molecular Medicine, vol. 16, no. 2, pp. 237–243, 2005.

[26] D. D. Xu, P. J. Zhou, Y. Wang et al., “miR-150 suppresses the proliferation and tumorigenicity of leukemia stem cells by targeting the Nanog signaling pathway,” Frontiers in Pharmacology, vol. 7, no. 439, 2016.

[27] H. Wang, L. Wang, S. Zhang, Z. Xu, and G. Zhang, “Downregulation of LINC00665 confers decreased cell proliferation and invasion via the miR-138-5p/E2F3 signaling pathway in NSCLC,” Biomedicine & Pharmacotherapy, vol. 127, no. 110214, p. 110214, 2020.

[28] K. Qi, Y. Li, K. Huang et al., “Pre-aplication of arsenic trioxide-maypotentiacteytotoxiciteffectsofvinorelbine/docetaxelneuroobloma SK-N-SHcells,” Biomedicine & Pharmacotherapy, vol. 113, no. 108665, 2019.

[29] C. Zeng, F. Pan, and L. A. Jones, “Evaluation of 5-ethyl-2’-deoxouridine staining as a sensitive and reliable method for studying cell proliferation in the adult nervous system,” Brain Research, vol. 1319, no. 11, pp. 21–32, 2010.

[30] X. W. Zhang, W. Qin, W. J. Gou, J. F. Li, B. Y. Liu, and F. C. Zhang, “Effect of Bmi-1 gene on the proliferation of gastric cancer cells and its mechanism,” World Chinese Journal of Digestology, vol. 17, no. 14, pp. 1390–1393, 2009.

[31] Y. Zhang, W. W. Luo, K. Wang, and J. Shi, “Overexpression of histone deacetylase 11 suppresses basal-like breast cancer cell invasion and metastasis,” J South Med Univ, vol. 39, no. 7, pp. 751–759, 2019.

[32] Q. S. Wang, Y. Xia, and H. X. Chen, “LINC01296 regulates Wnt/β-catenin signaling pathway and affects SK-N-SH cell proliferation, apoptosis, migration and invasion,” Chinese Journal of Cell Biology, vol. 42, no. 12, pp. 2116–2125, 2020.

[33] Z. Lin, H. Yang, Q. Kong et al., “USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development,” Molecular Cell, vol. 46, no. 4, pp. 484–494, 2012.

[34] X. Bi, Q. Ye, D. Li et al., “Inhibition of nuclear stress response by Sirt1: a potential mechanism of acetylation-independent regulation of p53 accumulation,” Aging Cell, vol. 18, no. 2, p. e12900, 2019.

[35] S. Libert and L. Guarente, “Metabolic and neuropsychiatric effects of calorie restriction and sirtuins,” Annual Review of Physiology, vol. 75, no. 1, pp. 669–684, 2013.

[36] M. Schott and C. Petersen, “New criteria for Alzheimer’s disease: which, when and why?,” Brain, vol. 138, no. 5, pp. 1134–1137, 2015.

[37] J. Shen, Y. Li, C. Qu, L. Xu, H. Sun, and J. Zhang, “The enriched environment ameliorates chronic unpredictable mild stress-induced depressive-like behaviors and cognitive impairment by activating the SIRT1/miR-134 signaling pathway in hippocampus,” Journal of Affective Disorders, vol. 248, pp. 81–90, 2019.

[38] D. Kim, M. D. Nguyen, M. M. Dobbin et al., “SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer’s disease and amyotrophic lateral sclerosis,” EMBO Journal, vol. 26, no. 13, pp. 3169–3179, 2007.

[39] B. Gomes, J. Silva, C. Remeiro et al., “Neuroprotective mechanisms of resveratrol in Alzheimer’s disease: role of SIRT1,” Oxidative Medicine and Cellular Longevity, vol. 2018, Article ID 815273, 15 pages, 2018.

[40] Q. Li, J. Zeng, M. Su, Y. He, and B. Zhu, “Acetylationshikonin from Zicao attenuates cognitive impairment and hippocampus senescence in d-galactose-induced aging mouse model via upregulating the expression of SIRT1,” Brain Research Bulletin, vol. 137, pp. 311–318, 2018.

[41] B. Jablonska, M. Gierdalski, L. J. Chew et al., “Sirt1 regulates glial progenitor proliferation and regeneration in white matter after neonatal brain injury,” Nature Communications, vol. 7, no. 1, 2016.

[42] S. H. Cho, J. A. Chen, F. Sayed et al., “SIRT1 deficiency in microglia contributes to cognitive decline in aging and neurodegeneration via epigenetic regulation of IL-1β,” The Journal of Neuroscience, vol. 35, no. 2, pp. 807–818, 2015.

[43] J. Yuan, K. Minter-Dykhouse, and Z. K. Lou, “A c-Myc–SIRT1 feedback loop regulates cell growth and transformation,” The Journal of Cell Biology, vol. 185, no. 2, pp. 203–211, 2009.

[44] E. Conrad, T. Polonio-Vallon, M. Meister et al., “Histone deacetylation-regulated interplay between p53 and its acetylation,” Cancer Letters, vol. 363, no. 2, pp. 108–118, 2015.

[45] D. Wang, N. Kon, G. Lasso et al., “Acetylation-regulated interaction between p53 and SET reveals a widespread regulatory mode,” Nature, vol. 538, no. 7623, pp. 118–122, 2016.

[46] M. Hernandez-Jimenez, O. Hurtado, M. I. Cuartero et al., “Silent information regulator 1 protects the brain against cerebral ischemic damage,” Stroke, vol. 44, no. 8, pp. 2333–2337, 2013.

[47] Y. Feng, T. Liu, S. Y. Dong et al., “Rotenone affects p53 transcriptional activity and apoptosis via targeting SIRT1 and H3K9 acetylation in SH-SY5Y cells,” Journal of Neurochemistry, vol. 134, no. 4, pp. 668–676, 2015.